Comparison of immunophenotyping between AML patients with and without the IDH1 mutation
| Variant . | Percentage of patients with the antigen expression . | P . | ||
|---|---|---|---|---|
| Total patients . | IDH1-mutated patients . | IDH1 wild-type patients . | ||
| HLA-DR | 67.4 (328/487) | 40.7 (11/27) | 68.9 (317/460) | .002 |
| CD34 | 64.3 (302/470) | 55.6 (15/27) | 65.2 (287/440) | .308 |
| CD13 | 94.3 (445/472) | 81.5 (22/27) | 95.1 (423/445) | .003 |
| CD33 | 91.3 (430/471) | 92.6 (25/27) | 91.2 (405/444) | .805 |
| CD11b | 31.1 (46/148) | 28.6 (2/7) | 31.2 (44/141) | .882 |
| CD14 | 13.1 (60/458) | 0 (0/27) | 13.9 (60/431) | .038 |
| CD15 | 43.8 (204/466) | 25.9 (7/27) | 44.9 (197/439) | .054 |
| CD19 | 6.7 (31/465) | 7.4 (2/27) | 6.6 (29/438) | .874 |
| CD7 | 19.9 (92/463) | 8.3 (2/24) | 20.5 (90/439) | .146 |
| CD2 | 4.2 (19/454) | 3.8 (1/26) | 4.2 (18/428) | .929 |
| CD56 | 22.8 (96/421) | 8.7 (2/23) | 23.6 (94/398) | .097 |
| Variant . | Percentage of patients with the antigen expression . | P . | ||
|---|---|---|---|---|
| Total patients . | IDH1-mutated patients . | IDH1 wild-type patients . | ||
| HLA-DR | 67.4 (328/487) | 40.7 (11/27) | 68.9 (317/460) | .002 |
| CD34 | 64.3 (302/470) | 55.6 (15/27) | 65.2 (287/440) | .308 |
| CD13 | 94.3 (445/472) | 81.5 (22/27) | 95.1 (423/445) | .003 |
| CD33 | 91.3 (430/471) | 92.6 (25/27) | 91.2 (405/444) | .805 |
| CD11b | 31.1 (46/148) | 28.6 (2/7) | 31.2 (44/141) | .882 |
| CD14 | 13.1 (60/458) | 0 (0/27) | 13.9 (60/431) | .038 |
| CD15 | 43.8 (204/466) | 25.9 (7/27) | 44.9 (197/439) | .054 |
| CD19 | 6.7 (31/465) | 7.4 (2/27) | 6.6 (29/438) | .874 |
| CD7 | 19.9 (92/463) | 8.3 (2/24) | 20.5 (90/439) | .146 |
| CD2 | 4.2 (19/454) | 3.8 (1/26) | 4.2 (18/428) | .929 |
| CD56 | 22.8 (96/421) | 8.7 (2/23) | 23.6 (94/398) | .097 |